KURA · Kura Oncology, Inc.

The thesis

Kura Oncology's case rests on KOMZIFTI, its leukemia drug, growing past the $9.1 million of second-quarter 2026 sales. The third-quarter report, expected around 10 November 2026 (company date unconfirmed), settles it. The shares closed at $9.86 on 22 October 2026, 27.4% below the 52-week high of $13.59, with a 14-day relative strength index of 37.7 (adjusted daily closes).

Analyst targets sit far above the price. JP Morgan initiated at Overweight with a $30 target on 1 October 2026, Wedbush's target is $38 (13 August 2026) and Citizens' is $24 (24 August 2026). MarketBeat reported a $25.46 average target across 13 analysts on 22 July 2026.

The narrative is maturing: the launch figures from 12 August 2026 are known, the Caspian diabetes financing of 9 September 2026 has been absorbed, and the shares have slipped from $10.60 on 9 October 2026 to $9.86 despite the new JP Morgan coverage. Only two full commercial quarters exist, which is too few to establish a growth rate. The view is that the third-quarter revenue line decides the direction; a figure at or below $9.1 million would invalidate it.

Bullish and bearish views on Kura Oncology, Inc.

The bull case on Kura Oncology, Inc. (KURA), in brief: Launch revenue is rising. The bear case: Product sales are small against losses.

Bull case

• Launch revenue is rising. Kura reported $9.1 million of second-quarter 2026 net KOMZIFTI revenue on 12 August 2026, up from $5.8 million in the first quarter, with approximately 115 new patient starts.
• Sell-side coverage is widening. JP Morgan began coverage on 1 October 2026 with an Overweight rating and a $30 target (Benzinga). Citizens reiterated Market Outperform with a $24 target on 24 August 2026. Wedbush raised its target to $38 on 13 August 2026.
• Cash is substantial. Kura reported $519.0 million of cash and short-term investments at the end of the second quarter, plus $180 million of anticipated Kyowa Kirin collaboration payments (12 August 2026 results).
• Frontline testing is scheduled. Kura's 12 August 2026 update placed further KOMET-007 and KOMET-008 combination datasets in the second half of 2026. Topline from the Phase 3 KOMET-017 trial is anticipated in 2028.
• Diabetes work has outside funding. Caspian Therapeutics raised $50 million, led by BVF Partners with Eli Lilly participating, and Kura keeps about half of the ownership (company announcement, 9 September 2026). On 13 October 2026 the two companies said they plan to devise a development strategy for the preclinical KO-7246.

Bear case

• Product sales are small against losses. Kura reported a second-quarter net loss of $68.3 million against $9.1 million of KOMZIFTI revenue and $11.8 million of collaboration revenue. Total sales of $20.874 million missed the $21.420 million estimate, while earnings per share of $(0.77) beat the $(0.87) estimate (Benzinga, 12 August 2026).
• The runway leans on partner payments. Kura's 12 August 2026 statement on how long its cash lasts depends in part on $180 million of anticipated Kyowa Kirin payments. Product sales alone do not fund operations.

• Competing menin inhibitors are moving toward frontline use. Revumenib and bleximenib are the class rivals. Evidence that frontline use is shifting toward them would weaken the long-term case for KOMZIFTI.
• Leadership is changing. Kura named Jennifer Fulk chief financial officer, effective 8 September 2026 (Benzinga).

Price setup

The shares closed at $9.86 on 22 October 2026, 27.4% below the 52-week high of $13.59. The 3-month price change is -2.9%. The 14-day relative strength index was 37.7, up from 26.1 on 9 October 2026 but still in the lower part of its range.

The post-approval trading range has a lower edge near $9.50. The 22 October 2026 close sits 3.7% above that level. A weekly close below it would mean the range has failed.

Crowding evidence is limited. Moves since early September have been a steady decline rather than a spike, and no insider selling or share issuance appears in recent news. The imminent third-quarter earnings date is the main event risk.

Catalysts, next 30 days

• ~10 November 2026, est.: third-quarter 2026 results. Kura reported on 12 May 2026 and 12 August 2026, so a mid-November date is likely but the company has not confirmed it. The KOMZIFTI product-revenue line is compared with $9.1 million.
• 31 December 2026: deadline for KOMET-007 and KOMET-008 combination datasets. This falls outside 30 days but frames the frontline-use argument that supports the higher analyst targets.

What would change the view

The case breaks if third-quarter KOMZIFTI product revenue is at or below the $9.1 million reported for the second quarter, or if the shares close a week below $9.50, the lower edge of the post-approval range. Either would show launch growth has stalled.

A third-quarter figure well above $9.1 million with continued patient-start growth would strengthen the case. Frontline data or label expansion for revumenib or bleximenib would weaken the long-term argument.

What it trades with

Kura trades with small- and mid-cap oncology biotech shares and responds to sentiment toward the XBI biotech index. Its direct comparison group is the other menin inhibitors, revumenib and bleximenib. Eli Lilly's participation in the Caspian financing is a separate, preclinical link and does not tie Kura's price to Lilly's.